As a result, ~19% of cancer patients harbor a RAS mutation, with KRAS accounting for 75% of RAS-mutant cancers, while NRAS (17%) and HRAS (7%) are associated with a smaller subset [5]. This evidence concerns the gene KRAS and cancer.